EM-800

• Description:

  EM-800, an orally active anti-estrogen, serves as an antagonist to the transcriptional functions of estrogen receptors α (ERα) and β (ERβ) . EM-800 possesses anticancer activity, capable of inhibiting the growth of breast cancer induced by 7,12-Dimethylbenz[a]anthracene (DMBA) (HY-W011845) . Furthermore, in ovariectomized animals, EM-800 effectively slows down bone loss. Additionally, EM-800 shows potential in the research of breast and endometrial cancers, while exerting beneficial effects on bone and lipid metabolism[1][2].

• UNSPSC:

  12352005

• Target:

  Estrogen Receptor/ERR

• Type:

  Reference compound

• Related Pathways:

  Vitamin D Related/Nuclear Receptor

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/em-800.html

• Smiles:

  CC(C)(C(OC1=CC2=C(C(C)=C([C@@H](O2)C3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)OC(C(C)(C)C)=O)C=C1)=O)C

• Molecular Formula:

  C39H47NO6

• Molecular Weight:

  625.79

• References & Citations:

  [1]Tremblay A, et al. EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta. Endocrinology. 1998 Jan;139 (1) :111-8.|[2]Labrie F, et al. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol. 1999 Apr-Jun;69 (1-6) :51-84.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 3

• CAS Number:

  182167-03-9